Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis

被引：0
作者：
Antonio Giovanni Solimando
Nicola Susca
Antonella Argentiero
Oronzo Brunetti
Patrizia Leone
Valli De Re
Rossella Fasano
Markus Krebs
Elisabetta Petracci
Irene Azzali
Oriana Nanni
Nicola Silvestris
Angelo Vacca
Vito Racanelli
机构：
[1] Aldo Moro University of Bari,Guido Baccelli Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, School of Medicine
[2] IRCCS Istituto Tumori Giovanni Paolo II of Bari,Bio
[3] Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS,Proteomics Facility, Department of Translational Research
[4] Aldo Moro University of Bari,Department of Biomedical Sciences and Human Oncology, School of Medicine
[5] University Hospital Würzburg,Comprehensive Cancer Center Mainfranken
[6] Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) IRCCS,Unit of Biostatistics and Clinical Trials
来源：
Clinical and Experimental Medicine | 2022年 / 22卷
关键词：
Hepatocellular carcinoma; Second-line treatment; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 74
页数：9
相关论文
共 172 条
  • [1] Rimassa L(2020)Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma Liver Int 40 1800-1811
  • [2] Wörns M-A(2019)Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma J Exp Clin Cancer Res 38 447-89
  • [3] Liu Z(2019)Carcinogenesis and Metastasis in Liver: Cell Physiological Basis Cancers (Basel). 11 1731-338
  • [4] Lin Y(2017)Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis J Carcinog 16 1-390
  • [5] Zhang J(2014)Treatment algorithms for managing hepatocellular carcinoma J Clin Exp Hepatol 4 S80-1173
  • [6] Zhang Y(1999)Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 329-1905
  • [7] Li Y(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-319
  • [8] Liu Z(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 391 1163-2502
  • [9] Rossetto A(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 382 1894-952
  • [10] De Re V(2020)Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma J Hepatol 72 307-66
12345678910